ESR1 and breast carcinoma: Naringenin was found to inhibit the growth and migration of both ER-negative (MDA-MB-453, MDA-MB-231) and ER-positive (MCF-7) breast cancer cells in vitro and in vivo [142,144,145,146,147,148,149,150,151,152,153].